文献速递姑息放疗与转移瘤头颈部肿瘤放疗

分化型甲状腺癌骨转移的放疗剂量效应研究

Radiotherapy for the management of bone metastases in differentiated thyroid cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-03-04

该回顾性研究纳入2003至2023年间107例分化型甲状腺癌(DTC)患者的280处骨转移灶,评估放疗剂量与技术对局部控制的影响。结果显示高BED10(≥40)治疗与显著更低的进展累积发生率相关(HR 0.50,p=0.003),低BED10组中位进展时间3.3年,高BED10组未达到。

要点

  • 高BED10≥40放疗与DTC骨转移进展风险显著降低相关(HR 0.50,p=0.003)。
  • 低BED10<40组中位进展时间3.3年,高BED10组未达到。
  • 条件允许时,DTC骨转移放疗应采用超过BED10=40的较高剂量。

核心结论

  • DTC骨转移患者存在明确的放疗剂量-效应关系,高BED10≥40治疗与更低的进展累积发生率相关。

研究设计与样本

  • 单中心回顾性队列研究,纳入2003至2023年Princess Margaret癌症中心107例DTC患者的280处骨转移灶。
  • 主要终点为治疗转移灶控制(TMC),从放疗完成日期计算至病灶进展、死亡或末次随访。
  • 以BED10(α/β=10)比较放疗方案,按BED10<40(低剂量,n=72)与BED10≥40(高剂量,n=35)分组。
  • 采用Aalen-Johansen法估计TMC累积发生率,Gray检验比较两组,单因素及多因素模型评估TMC预测因素,双侧p<0.05为统计学显著。

主要发现

  • 高BED10≥40组进展累积发生率显著低于低BED10<40组(HR 0.50,p=0.003)。
  • 低BED10<40组中位进展时间为3.3年,高BED10≥40组未达到。
  • 107例患者中55例进行了分子检测,未发现可预测TMC的突变。

关键数值与推荐

  • BED10≥40定义为高剂量放疗,BED10<40定义为低剂量放疗。
  • 剂量-效应关系以BED10作为连续变量、按10为增量进行评估。

临床怎么用

  • 对适合放疗的DTC骨转移患者,应优先考虑BED10超过40的较高剂量方案。
  • 对放射性碘难治、进展或有症状的DTC骨转移,外照射放疗是可选局部治疗手段。

局限性

  • 本研究为单中心回顾性队列研究,样本来自Princess Margaret癌症中心。
  • 分子检测仅在55/107例患者中进行,未发现可预测TMC的突变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Bone metastases are observed in over 50% of patients with differentiated thyroid cancer (DTC) who develop metastatic disease. Local treatments including external beam radiation therapy (RT) may be used for radioactive iodine-refractory, progressive, or symptomatic disease. The purpose of this study was to evaluate the efficacy of radiotherapy doses and techniques for DTC bone metastases. MATERIALS AND METHODS: This retrospective study included all patients with DTC who received RT for bone metastases. The primary outcome was treated metastasis control (TMC), calculated from the date of radiotherapy completion to the date of lesion progression, death, or last follow-up. The biological effective dose (BED, α/β = 10) was used to compare radiotherapy regimens. The dose-response relationship was evaluated using BED10 as a continuous variable in increments of 10. Subsequently, the group was divided into low-dose radiation (BED10 < 40) and high-dose radiation (BED10 ≥ 40). The cumulative incidence of TMC was estimated using the Aalen-Johansen method and compared between two BED groups using the Gray test. Univariate and multivariate models were performed to assess for predictors of TMC. A two-sided p-value of < 0.05 was considered statistical significance. RESULTS: In total, 107 patients with DTC were treated for 280 bone metastases between 2003 and 2023. Patients were stratified into two groups: high BED10 ≥ 40 (n = 35) and low BED10 < 40 (n = 72). Our results demonstrated that high BED treatment was associated with significantly lower cumulative incidence of progression (HR 0.50, p = 0.003), with a median progression time of 3.3 years for low BED and not reached for high BED groups. In total 55/107 patients had molecular profiling, but no mutations were found to predict TMC. CONCLUSION: In this retrospective cohort study conducted at the Princess Margaret Cancer Center, a clear dose-response relationship was identified for patients with DTC bone metastases. When suitable, treatment of these patients should include a higher dose exceeding BED10 = 40.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Faulkner C, Mesci A, Alfadli F, et al. Radiotherapy for the management of bone metastases in differentiated thyroid cancer. Clin Transl Radiat Oncol. 2026. PMID: 41868579. doi:10.1016/j.ctro.2026.101139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。